Evaluation of orelabrutinib monotherapy in patients with relapsed or refractory Waldenström's macroglobulinemia in a single-arm, multicenter, open-label, phase 2 study-Reference-Cited by-同舟云学术

Evaluation of orelabrutinib monotherapy in patients with relapsed or refractory Waldenström's macroglobulinemia in a single-arm, multicenter, open-label, phase 2 study

Published:2022-10 Issue: Volume:52 Page:101682
ISSN:2589-5370
Container-title:eClinicalMedicine
language:en
Short-container-title:eClinicalMedicine

Author:

Cao Xin-xin^ORCID,Jin Jie,Fu Cheng-cheng,Yi Shu-hua,Zhao Wei-li,Sun Zi-min,Yang Wei,Li Deng-ju,Cui Guo-hui,Hu Jian-da,Liu Ting,Song Yong-ping,Xu Bing,Zhu Zun-min,Xu Wei,Zhang Ming-zhi,Tian Ya-min,Zhang Bin,Zhao Ren-bin,Zhou Dao-bin^ORCID

Publisher

Elsevier BV

Subject

General Medicine

Reference31 articles.

1. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the second international workshop on Waldenstrom's Macroglobulinemia;Owen;Semin Oncol,2003

2. Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013 featured updates to the NCCN guidelines;Anderson;J Natl Compr Canc Netw,2012

3. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia;Treon;Blood,2014

4. Genomic landscape of Waldenström macroglobulinemia and its impact on treatment strategies;Treon;J Clin Oncol,2020

5. CXCR4 in Waldenström's macroglobulinema: chances and challenges;Kaiser;Leukemia,2021

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comprehensive Characterization of BTK Inhibitor Specificity, Potency, and Biological Effects: Insights into Covalent and Non-covalent Mechanistic Signatures;2024-09-08

2. Impact of Chromosomal Aberrations Detected by Chromosome Banding Analysis in Symptomatic Waldenström’s Macroglobulinemia;2024-08-17

3. Novel Approaches to Managing Patients with Relapsed and Refractory Waldenström Macroglobulinemia;Current Hematologic Malignancy Reports;2024-07-06

4. Evidence-based expert consensus on clinical management of safety of Bruton's tyrosine kinase inhibitors (2024);CHINESE J CANCER RES;2024

5. Optimizing BTK Inhibition in Waldenström Macroglobulinemia;Journal of the National Comprehensive Cancer Network;2024-05